|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li CI, Anderson BO, Daling JR and Moe RE:
Trends in incidence rates of invasive lobular and ductal breast
carcinoma. JAMA. 289:1421–1424. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kohler BA, Ward E, McCarthy BJ, Schymura
MJ, Ries LA, Eheman C, Jemal A, Anderson RN, Ajani UA and Edwards
BK: Annual report to the nation on the status of cancer, 1975–2007,
featuring tumors of the brain and other nervous system. J Nat
Cancer Inst. 103:714–736. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang YC, Wei LJ, Liu JT, Li SX and Wang
QS: Comparison of cancer incidence between China and the USA.
Cancer Biol Med. 9:128–132. 2012.PubMed/NCBI
|
|
5
|
Linos E, Spanos D, Rosner BA, Linos K,
Hesketh T, Qu JD, Gao YT, Zheng W and Colditz GA: Effects of
reproductive and demographic changes on breast cancer incidence in
China: A modeling analysis. J Natl Cancer Inst. 100:1352–1360.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
McPherson K, Steel CM and Dixon JM: ABC of
breast diseases. Breast cancer-epidemiology, risk factors, and
genetics. BJM. 321:624–628. 2000. View Article : Google Scholar
|
|
7
|
Chia KS, Reilly M, Tan CS, Lee J, Pawitan
Y, Adami HO, Hall P and Mow B: Profound changes in breast cancer
incidence may reflect changes into a Westernized lifestyle: A
comparative population-based study in Singapore and Sweden. Int J
Cancer. 113:302–306. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pérez-Tenorio G and Stål O; Southeast
Sweden Breast Cancer Group, : Activation of AKT/PKB in breast
cancer predicts a worse outcome among endocrine treated patients.
Br J Cancer. 86:540–545. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Song G, Ouyang G and Bao S: The activation
of Akt/PKB signaling pathway and cell survival. J Cell Mol Med.
9:59–71. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Roudier E, Mistafa O and Stenius U:
Statins induce mammalian target of rapamycin mTOR)-mediated
inhibition of Akt signaling and sensitize p53-deficient cells to
cytostatic drugs. Mol Cancer Ther. 5:2706–2715. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mondesire WH, Jian W, Zhang H, Ensor J,
Hung MC, Mills GB and Meric-Bernstam F: Targeting mammalian target
of rapamycin synergistically enhances chemotherapy-induced
cytotoxicity in breast cancer cells. Clin Cancer Res. 10:7031–7042.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Vestey SB, Sen C, Calder CJ, Perks CM,
Pignatelli M and Winters ZE: Activated Akt expression in breast
cancer: Correlation with p53, Hdm2 and patient outcome. Eur J
Cancer. 41:1017–1025. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tokunaga E, Kimura Y, Oki E, Ueda N,
Futatsugi M, Mashino K, Yamamoto M, Ikebe M, Kakeji Y, Baba H and
Maehara Y: Akt is frequently activated in HER2/neu-positive breast
cancers and associated with poor prognosis among hormone-treated
patients. Int J Cancer. 118:284–289. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Benesch C, Schneider C, Voelker HU, Kapp
M, Caffier H, Krockenberger M, Dietl J, Kammerer U and Schmidt M:
The clinicopathological andprognostic relevance of pyruvate kinase
M2 and pAkt expression in breast cancer. Anticancer Res.
30:1689–1694. 2010.PubMed/NCBI
|
|
15
|
Badve S, Collins NR, Bhat-Nakshatri P,
Turbin D, Leung S, Thorat M, Dunn SE, Geistlinger TR, Carroll JS,
Brown M, et al: Subcellular localization ofactivated AKT in
estrogen receptor- and progesterone receptor-expressing
breastcancers: Potential clinical implications. Am J Pathol.
176:2139–2149. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Levine B and Kroemer G: Autophagy in the
pathogenesis of disease. Cell. 132:27–42. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mizushima N, Levine B, Cuervo AM and
Klionsky DJ: Autophagy fights disease through cellular
self-digestion. Nature. 451:1069–1075. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nishimura K, Semba S, Aoyagi K, Sasaki H
and Yokozaki H: Mesenchymal stem cells provide an advantageous
tumor microenvironment for the restoration of cancer stem cells.
Pathobiology. 79:290–306. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Singletary SE, Allred C, Ashley P, Bassett
LW, Berry D, Bland KI, Borgen PI, Clark GM, Edge SB, Hayes DF, et
al: Staging system for breast cancer: Revisions for the 6th adition
of the AJCC cancer staging manual. Surg Clin North Am. 83:803–819.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Markman B, Atzori F, Pérez-García J,
Tabernero J and Baselga J: Status of PI3K inhibition and biomarker
development in cancer therapeutics. Ann Oncol. 21:683–691. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Altomare DA, Wang HQ, Skele KL, De Rienzo
A, Klein-Szanto AJ, Godwin AK and Testa JR: AKT and mTOR
phosphorylation is frequently detectedin ovarian cancer and can be
targeted to disrupt ovarian tumor cell growth. Oncogene.
23:5853–5857. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Verhaak RG, Tamayo P, Yang JY, Hubbard D,
Zhang H, Creighton CJ, Fereday S, Lawrence M, Carter SL, Mermel CH,
et al: Prognostically relevant gene signatures of high-grade
serouso varian carcinoma. J Clin Invest. 123:517–525.
2013.PubMed/NCBI
|
|
23
|
Woenckhaus J, Steger K, Sturm K, Münstedt
K, Franke FE and Fenic I: Prognostic value of PIK3 CA and
phosphorylated AKT expression in ovarian cancer. Virchows Arch.
450:387–395. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Azim HA, Kassem L, Treilleux I, Wang Q, El
Enein MA, Anis SE and Bachelot T: Analysis of PI3K/mTOR pathway
biomarkers and their prognostic value in women with hormone
receptor-positive, HER2-negative early breast cancer. Transl Oncol.
9:114–123. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen J, Xi B, Zhao Y, Yu Y, Zhang J and
Wang C: High-mobility group protein B1 (HMGB1) is a novel biomarker
for human ovarian cancer. Gynecol Oncol. 126:109–117. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jiang ZF, Shao LJ, Wang WM, Yan XB and Liu
RY: Decreased expression of Beclin-1 and LC3 in human lung cancer.
Mol Biol Rep. 39:259–267. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zarzynska JM: The importance of autophagy
regulation in breast cancer development and treatment. Biomed Res
Int. 2014:7103452014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ding ZB, Shi YH, Zhou J, Qiu SJ, Xu Y, Dai
Z, Shi GM, Wang XY, Ke AW, Wu B and Fan J: Association of autophagy
defect with a malignant phenotype and poor prognosis of
hepatocellular carcinoma. Cancer Res. 68:9167–9175. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dalby KN, Tekedereli I, Lopez-Berestein G
and Ozpolat B: Targeting the prodeath and prosurvival functions of
autophagy as novel therapeutic strategies in cancer. Autophagy.
6:322–329. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yoshioka A, Miyata H, Doki Y, Yamasaki M,
Sohma I, Gotoh K, Takiguchi S, Fujiwara Y, Uchiyama Y and Monden M:
LC3, an autophagosome marker, is highly expressed in
gastrointestinal cancers. Int J Oncol. 33:461–468. 2008.PubMed/NCBI
|
|
31
|
Fujii S, Mitsunaga S, Yamazaki M, Hasebe
T, Ishii G, Kojima M, Kinoshita T, Ueno T, Esumi H and Ochiai A:
Autophagy is activated in pancreatic cancer cells and correlates
with poor patient outcome. Cancer Sci. 99:1813–1819.
2008.PubMed/NCBI
|
|
32
|
Park JY, Kim HS, Cho H, Kim NC, Chae KH,
Park WS and Kim YW: Clinicopathologic correlation of
autophagy-related Beclin-1 expression in gallbladder cancer.
Hepatogastroenterology. 61:1494–1500. 2014.PubMed/NCBI
|
|
33
|
Jiang ZF, Shao LJ, Wang WM, Yan XB and Liu
RY: Decreased expression of Beclin-1 and LC3 in human lung cancer.
Mol Biol Rep. 39:259–267. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cheng HY, Zhang YN, Wu QL, Sun XM, Sun JR
and Huang X: Expression of beclin 1, an autophagy-related protein,
in human cervical carcinoma and its clinical significance. Eur J
Gynaecol Oncol. 33:15–20. 2012.PubMed/NCBI
|
|
35
|
Chen YB, Hou JH, Feng XY, Chen S, Zhou ZW,
Zhang XS and Cai MY: Decreased expression of Beclin 1 correlates
with a metastatic phenotypic feature and adverse prognosis of
gastric carcinomas. J Surg Oncol. 105:542–547. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen Y, Lu Y, Lu C and Zhang L: Beclin-1
expression is a predictor of clinical outcome in patients with
esophageal squamous cell carcinoma and correlated to
hypoxia-inducible factor HIF)-1alpha expression. Pathol Oncol Res.
15:487–493. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Osman NA, Abd El-Rehim DM and Kamal IM:
Defective Beclin-1 and elevated hypoxia-inducible factor (HIF)-1α
expression are closely linked to tumorigenesis, differentiation,
and progression of hepatocellular carcinoma. Tumour Biol.
36:4293–4299. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Mathew R, Karantza-Wadsworth V and White
E: Role of autophagy in cancer. Nat Rev Cancer. 7:961–967. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Degenhardt K, Mathew R, Beaudoin B, Bray
K, Anderson D, Chen G, Mukherjee C, Shi Y, Gélinas C, Fan Y, et al:
Autophagy promotes tumor cell survival and restricts necrosis,
inflammation, and tumorigenesis. Cancer Cell. 10:51–64. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lorin S, Hamaï A, Mehrpour M and Codogno
P: Autophagy regulation and its role in cancer. Semin Cancer Biol.
23:361–379. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Choi AM, Ryter SW and Levine B: Autophagy
in human health and disease. N Engl J Med. 368:651–662. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Liang XH, Jackson S, Seaman M, Brown K,
Kempkes B, Hibshoosh H and Levine B: Induction of autophagy and
inhibition of tumorigenesis by beclin 1. Nature. 402:672–676. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhang Y, Zhang Y, Xiu HQ, et al: Clinical
features of TNM staging of triple negative breast cancer and risk
factors affecting its prognosis. Chin J Breast Dis. 6:30–35.
2012.
|
